Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Morphosys Ag ADR SEMMELWEISSTR. 7 PLANEGG 2M 82152 DEU

www.morphosys.com P: 49-8989-9270 F: 898-992-7222

Description:

MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany.

Key Statistics

Overview:

Market Capitalization, $K 2,732,265
Enterprise Value, $K 2,562,495
Shares Outstanding, K 150,621
Annual Sales, $ 257,890 K
Annual Net Income, $ -205,350 K
Last Quarter Sales, $ 63,610 K
Last Quarter Net Income, $ 53,170 K
EBIT, $ -273,250 K
EBITDA, $ -261,850 K
60-Month Beta 1.16
% of Insider Shareholders 0.05%
% of Institutional Shareholders 18.38%
Float, K 150,546
% Float 99.95%
Short Volume Ratio 0.29

Growth:

1-Year Return 349.01%
3-Year Return -18.10%
5-Year Return -28.02%
5-Year Revenue Growth 185.66%
5-Year Earnings Growth -183.02%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.33 on 03/13/24
Latest Earnings Date 05/01/24
Earnings Per Share ttm -1.56
EPS Growth vs. Prev Qtr 134.74%
EPS Growth vs. Prev Year -85.53%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MOR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -694.31%
Return-on-Assets % -8.96%
Profit Margin % -79.63%
Debt/Equity 0.03
Price/Sales 10.59
Price/Cash Flow N/A
Price/Book 51.58
Book Value/Share 0.35
Interest Coverage -0.34
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar